2022 Have you considered joining MASCC? New member wondering where to start? Our Spanish-language webinar on how to make the most of your MASCC membership is now available as a free recording:
2022 Have you considered joining MASCC? New member wondering where to start? Our Spanish-language webinar on how to make the most of your MASCC membership is now available as a free recording:
2022 Newly published by the Palliative Care Study Group, this guideline provides evidence-based recommendations on the management of malignant bowel obstruction (MBO) for patients with advanced cancer.
2022 Congratulations to the "G. Mazzini" Hospital, Department of Oncology, Medical Oncology Unit in Teramo, Italy, our newest MASCC-Designated Center of Excellence in Supportive Care in Cancer.
2022 Every month, we share articles from the MASCC journal Supportive Care in Cancer. The “Editor’s Pick” section, chosen by the journal’s Editor-In-Chief, Dr. Fred Ashbury, PhD, will cover a variety of topics to meet the many interests of our membership. This month we feature:
2022 A number of clinically relevant findings of the landmark OraRad study have been published recently. OraRad is a large multicenter prospective cohort study examining oral complications after radiation therapy (RT) for head and neck cancer. The study team enrolled 572 participants, who were examined prior to RT and then every 6 months until 2 years after RT. Some of the most notable findings include:
2022 In this recording, learn how:
2022 We hope you’ll be joining us in Toronto from June 23-25 for our 2022 Annual Meeting*! The early bird registration deadline has been extended to April 20, 2022 - be sure to register by the deadline to take advantage of the reduced rate.
2022 Please note: This webinar will be in Spanish
2022 Recently published through Springer, Orofacial Supportive Care in Cancer: A Contemporary Oral Oncology Perspective is an easy-to-use book which will equip clinicians and health care professionals with all the information that they need to identify and manage orofacial complications of cancer therapy.
2022 Congratulations to the members of the Mucositis Guidelines Leadership Group! Their guidelines summary paper is acknowledged as a “top cited” paper for 2020-2021 in Cancer journal.
2022 The “Editor’s Pick” section is chosen by the journal’s Editor-In-Chief, Dr Fred Ashbury, PhD, and will cover a variety of topics to meet the many interests of our membership.
2022
2022 This is the last chance to submit abstracts for the MASCC/ISOO 2022 Annual Meeting
2022 We’re pleased to recognize our two newest MASCC-Designated Centers of Excellence in Supportive Care in Cancer:
2022 Every month, we share articles from the MASCC journal Supportive Care in Cancer. The “Editor’s Pick” section, chosen by the journal’s Editor-In-Chief, Dr. Fred Ashbury, PhD, will cover a variety of topics to meet the many interests of our membership. This month we feature:
2022 Register now for the MASCC/ISOO 2022 Annual Meeting to take advantage of early bird pricing! Join us in Toronto for three days of cutting-edge research, practical workshops, and lots of networking opportunities.
2022 Now available from the Mucositis Study Group, the MASCC/ISOO clinical practice guidelines for the management of mucositis (2019-2020) have been translated into 8 languages: Arabic, French, German, Greek, Japanese, Portuguese (Brazilian), Portuguese (Portugal), and Spanish.
This tool is an evidence-based tool to assist clinicians caring for patients prescribed oral anticancer agents. A companion user guide provides an introduction to the tool and explanation of how best to use the MOATT. The MOATT has now been translated into six languages and we encourage translations in other languages. Information on the MOATT, approval for use and translation policy are available on the MASCC website.
2022 Just published in the Brazilian Journal of Clinical Oncology, Care for patients with advanced cancer in the last weeks of life in Brazil was a collaborative effort between the MASCC Palliative Care Study Group and our partner SBOC.